

FINLAND

Recent and planned developments in pharmaceutical policies 2025/2026

CHANGES IN PRICING

Changes implemented 01/01/2025:

- The wholesale price of the first generic medicine is at most 40 % of the accepted wholesale price for the original medicinal product (previously 50 %).
- The wholesale prices of biological products are lowered (price at most 75 % of the highest accepted wholesale price for biosimilar) at the beginning of the next fourth quarter after the first reimbursed biosimilar is available on the market. At the same time the restriction of reimbursement will be re-evaluated and removal of restriction is possible.
- The VAT of medicines was increased from 10 % to 14 %.

Changes implemented 01/03/2025:

- 1,5 % price cut for reimbursed medicines that received marketing authorisation in 2010 or later with certain restrictions.

Changes implemented 01/01/2026:

- Pharmacy mark-ups of prescription medicines were lowered.
- The VAT of medicines was decreased to 13,5 %

CHANGES IN REIMBURSEMENT

Changes implemented 01/01/2025:

- The initial deductible on reimbursements for medicine expenses was increased from 50 euros to 70 euros.
- The regulation on conditional reimbursement was made permanent.

Changes implemented 01/01/2026:

- The initial deductible on reimbursements for medicine expenses was increased from 70 euros to 70.33 euros due to the increase in the National Pensions Index.

OTHER CHANGES

No other changes in 2025/2026.

Currently evaluation for outpatient medicines, inpatient medicines and vaccines are done separately by different authorities and with different evaluation criteria. There is ongoing a reform for harmonizing and updating the evaluation processes and criteria related to the adoption of medicines. The work for a new organisational structure is currently in the assessment phase for different options. The proposed models are a multi-actor model, a two-actor model and a single-actor model. The implementation timetable is not yet known in more detail.

SPECIAL TOPIC:

Regulation, pricing and reimbursement of pharmaceutical combination products

The regulation or pricing and reimbursement evaluation of a new medicinal product that contains two or more active substances does not differ from a product that contains only one active substance.

In outpatient care, if a new combination product contains active substances that are already reimbursed as individual products, the director of Pharmaceuticals Pricing Board may confirm a reasonable wholesale price for a new combination product provided that the wholesale price proposed for the product does not exceed the combined costs of products containing the same active substances (the delegation decision of Pharmaceuticals Pricing Board (March 6, 2025)).

No special challenges regarding this topic.